Penn State Cancer Patients Report Cannabis Eases Symptoms, Cuts Opioid Use

October 13, 2026 By Sy. O

How Cancer Patients at Penn State Are Turning to Cannabis for Symptom Relief-and Cutting Back on Opioids

A recent patient survey from the Penn State Cancer Institute reveals a notable shift: many cancer patients are turning to cannabis to ease symptoms like insomnia, poor appetite, mood disturbances and pain, with nearly one-third using it as a substitute for prescription opioids.

Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice.

Survey Breakdown: Rural and Urban Cannabis Use Alike

Between June 2023 and June 2024, 186 adult cancer patients at Penn State Cancer Institute completed anonymous paper questionnaires during clinic visits. Roughly a quarter reported using cannabis since their diagnosis, with similar usage rates across rural, suburban and urban residents-even though nearly half lived in rural Appalachian counties. This parity suggests that cannabis use among cancer patients may be widespread regardless of location and highlights the need for consistent, clinician-led guidance on product sourcing and safe use.

Symptom Relief: What Patients Reported

Insomnia: 89.7% reported improvement
Appetite: 85.7% improved
Mood: approximately 84% improved
Joint pain or stiffness: 83.3%
Stress, anxiety or depression: 81.6%
Cancer-related pain: 80.7%
Digestive symptoms: 67.9%

Other symptoms like fatigue, sexual interest, and hot flashes saw lower improvement rates, and fatigue was sometimes reported to worsen. These nuanced outcomes underline the complex effects cannabis may have depending on symptom type.

Opioid Substitution and Medication Reduction

Among respondents answering related questions, 30.1% said they had used cannabis instead of opioids for pain, and 32.0% reported reducing or stopping other medications. While these figures reflect patient-reported behavior rather than clinical outcomes, they point to a potential shift in how patients manage pain and medication.

Implications for Consumer Behavior and Brand Strategy

This study signals growing consumer interest in cannabis products for cancer-related symptom relief. For hemp-derived CBD/THC brands, this could mean increased demand for formulations targeting sleep, appetite, mood, and joint comfort. Retailers and producers may need to tailor product lines-perhaps offering inhalable formats or specific THC/CBD ratios-to align with these patient-reported benefits.

Shoppers Should Note

Many patients reported relief, but this is self-reported data-not clinical proof of efficacy.
Product composition varied: 45.6% cited delta-9 THC as their main component, 26.1% CBD, and 19.6% delta-8 THC; nearly 28% were unsure what they were using.
Smoking was the most common method-over half of users reported inhalation-which may raise questions about dosage consistency and safety.

What This Means for Hemp Wellness Shopping

For shoppers looking for symptom-targeted hemp products, this study suggests a growing demand for reliable, clearly labeled options that address sleep, appetite, mood, joint comfort, and pain. Brands that invest in transparency-lab testing, clear cannabinoid profiles, dosing guidance-stand to earn trust from consumers looking for alternatives to pharmaceuticals.

Spotlight items to consider:
Tillmans Tranquils Relax Gummies Mango - 20 Count, 20mg CBD, 2mg THC (Gummies)
Tillmans Tranquils Euphoria Gummies - 15 count, 250mg CBD, 10mg THC (Gummies)

Also, check our broader ChowIndex: Hemp Product Directory and learn which brands and products are trending in rankings via ChowIndex: Brand & Product Rankings.

Q: Can these self-reported improvements be taken as evidence that cannabis works for cancer symptoms?; No-while the survey shows patients felt relief, these are subjective reports. Clinical trials are needed to establish safety and efficacy.
Q: Does product type or cannabinoid profile matter for different symptoms?; Probably. Since patients used delta-9 THC, CBD, and delta-8 THC with varying effects, shoppers should choose products with clear cannabinoid ratios and formats suited to their needs.
Q: Should rural shoppers expect different outcomes than urban ones?; The study found no significant difference in reported symptom relief by area. But rural users may need better access to education and product guidance.
Q: Is inhalation the best way to use these products?; Not necessarily. While smoking was common in the study, other formats like gummies or tinctures offer more controlled dosing and may suit different preferences.
Q: Does this study mean I can reduce my opioid use?; Patients reported doing so, but that doesn't mean it's safe or appropriate. Always consult with a healthcare provider before changing any medication regimen.

As consumer demand for symptom-targeted hemp products grows, brands that prioritize transparency, lab testing, and user education will likely lead the market. This Penn State survey offers a snapshot of patient behavior-but the next step will be clinical trials to turn anecdote into evidence.